Movement Disorders Therapeutics
1. Austedo patent expiration
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia
AUSTEDO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11564917 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US12016858 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11648244 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(12 years from now) | |
| US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11813232 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(12 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US11666566 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
|
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US8524733 (Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(5 years from now) | |
|
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US11813232 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(12 years from now) | |
|
US10959996 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11564917 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11179386 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(12 years from now) | |
|
US11666566 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US11648244 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11446291 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11357772 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US12016858 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Dosage: TABLET
How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage
AUSTEDO family patents
2. Azilect patent expiration
Treatment: Treatment of parkinson's disease
AZILECT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5453446 | TEVA | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. |
Feb, 2017
(8 years ago) | |
| US6126968 | TEVA | Stable compositions containing N-propargyl-1-aminoindan |
Sep, 2016
(9 years ago) | |
| US5532415 | TEVA | R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof |
Jul, 2013
(12 years ago) | |
| US7572834 | TEVA | Rasagiline formulations and processes for their preparation |
Dec, 2026
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-685) | May 29, 2017 |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Dosage: TABLET
More Information on Dosage
AZILECT family patents
3. Comtan patent
expiration
Treatment: Treatment of parkinson's disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5446194 | ORION PHARMA | Pharmacologically active catechol derivatives |
Oct, 2013
(12 years ago) | |
| US6599530 | ORION PHARMA | Oral compacted composition comprising catechol derivatives |
Sep, 2018
(7 years ago) | |
Drugs and Companies using ENTACAPONE ingredient
Market Authorisation Date: 19 October, 1999
Dosage: TABLET
How can I launch a generic of COMTAN before it's drug patent expiration?
More Information on Dosage
COMTAN family patents
4. Horizant patent expiration
Treatment: Management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults
HORIZANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(9 months ago) | |
| US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(3 years ago) | |
| US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(2 months from now) | |
| US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(11 months ago) | |
| US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
5. Ingrezza patent expiration
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10851104 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(10 years from now) | |
| US10844058 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(10 years from now) | |
| US10851103 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(10 years from now) | |
| US10065952 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(10 years from now) | |
| US10906902 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(10 years from now) | |
| US8039627 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Apr, 2031
(5 years from now) | |
| US10919892 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(10 years from now) | |
| US10906903 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US11654142 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Nov, 2038
(12 years from now) | |
| US11026939 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(12 years from now) | |
| US8357697 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Nov, 2027
(1 year, 9 months from now) | |
| US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(14 years from now) | |
| US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US11439629 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US11311532 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(12 years from now) | |
| US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(13 years from now) | |
| US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
| New Indication(I-925) | Aug 18, 2026 |
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Dosage: CAPSULE
How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage
INGREZZA family patents
6. Neupro patent expiration
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of r...
NEUPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6884434 | UCB INC | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
Mar, 2021
(4 years ago) | |
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(2 years ago) | |
| US7413747 | UCB INC | Transdermal therapeutic system for treating Parkinsonism |
Mar, 2019
(6 years ago) | |
| US6699498 | UCB INC | Transdermal therapeutic systems having improved stability and their production |
Nov, 2020
(5 years ago) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(1 year, 7 months from now) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(a month ago) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(4 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(6 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-646) | Apr 02, 2015 |
| New Indication(I-647) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Dosage: FILM, EXTENDED RELEASE
How can I launch a generic of NEUPRO before it's drug patent expiration?
More Information on Dosage
NEUPRO family patents
7. Nourianz patent expiration
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7727994 | KYOWA KIRIN | Methods of treating patients suffering from movement disorders |
Jan, 2023
(2 years ago) | |
| US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2028
(2 years from now) | |
| US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Dosage: TABLET
More Information on Dosage
NOURIANZ family patents
8. Nuplazid patent expiration
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Trea...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6756393 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US7115634 | ACADIA PHARMS INC | 4-aminopiperidine and their use as a medicine |
Oct, 2021
(4 years ago) | |
| US9296694 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US6815458 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US7858789 | ACADIA PHARMS INC | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec, 2020
(5 years ago) | |
| US8110574 | ACADIA PHARMS INC | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec, 2020
(5 years ago) | |
| US7732615 | ACADIA PHARMS INC | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Jun, 2028
(2 years from now) | |
| US7923564 | ACADIA PHARMS INC | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Sep, 2025
(3 months ago) | |
| US7601740 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Apr, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9765053 | ACADIA PHARMS INC | Methods of treatment using selective 5-HT2A inverse agonists |
Jul, 2022
(3 years ago) | |
| US10028944 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(11 years from now) | |
| US7659285 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Aug, 2026
(7 months from now) | |
| US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(11 years from now) | |
| US8921393 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US8618130 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US9566271 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US10849891 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US11452721 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US10646480 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US10449185 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Dosage: CAPSULE; TABLET
How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage
NUPLAZID family patents
9. Ongentys patent expiration
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes; Adjunctive t...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9630955 | AMNEAL | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(6 years from now) | |
| US8168793 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(3 years from now) | |
| US8907099 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357468 | AMNEAL | Medicaments for slowing Parkinson's disease |
May, 2035
(9 years from now) | |
| US9745290 | AMNEAL | Dosage regimen for COMT inhibitors |
Oct, 2027
(1 year, 8 months from now) | |
| US9550759 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(6 months from now) | |
| US8524746 | AMNEAL | Dosage regimen for COMT inhibitors |
Jul, 2029
(3 years from now) | |
| US10583130 | AMNEAL | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(4 years from now) | |
| US12129247 | AMNEAL | Administration regime for nitrocatechols |
Jan, 2032
(6 years from now) | |
| US10071085 | AMNEAL | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Dosage: CAPSULE
More Information on Dosage
ONGENTYS family patents
10. Xadago patent expiration
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8278485 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Jun, 2027
(1 year, 4 months from now) | |
| US8076515 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283380 | MDD US | Methods for treatment of parkinson's disease |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2022 |
Drugs and Companies using SAFINAMIDE MESYLATE ingredient
NCE-1 date: 21 March, 2021
Market Authorisation Date: 21 March, 2017
Dosage: TABLET
More Information on Dosage
XADAGO family patents